By Dominic Tyer (European Pharmaceutical Review)2025-09-01T11:06:01
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-29T14:00:00Z 2026-04-29T15:00:00Z
Sponsored by USP
2026-06-10T15:00:00Z 2026-06-10T16:00:00Z
Sponsored by BioDuro
2026-04-14T12:32:00Z
Sponsored by Thermo Fisher Scientific
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-09-17T08:00:00
Sponsored by Mastercontrol
2025-09-19T15:55:00
Sponsored by Sartorius, By Marko Narobe (Sartorius Biosepartions), Michael Gerrero (BridgeBio) and Srivatsan Ramesh (BridgeBio)
2025-07-16T11:00:00
Sponsored by USP
2025-10-08T07:00:00
Sponsored by Entegris
Site powered by Webvision Cloud